NewAmsterdam Pharma

NewAmsterdam Pharma's mission is to develop innovative oral therapies for cardiovascular and lipid-related diseases, targeting the large population of patients failing to achieve LDL-C goals. Its core achievement is the late-stage development of obicetrapib, a CETP inhibitor with compelling Phase 3 efficacy and safety data, supported by over $1.2 billion in total capital raised. The company's strategy involves securing regulatory approval, preparing for a U.S. launch, and leveraging ex-U.S. partnerships like the one with Menarini Group to maximize global commercial potential.

Focused on the development of next-generation, oral cholesteryl ester transfer protein (CETP) inhibitors, a mechanism validated by human genetic data linking CETP loss-of-function to reduced cardiovascular risk.

Competes directly with oral PCSK9 inhibitors (e.g., Merck's MK-0616), injectable PCSK9 mAbs, bempedoic acid, and other lipid-lowering agents. Differentiation is based on obicetrapib's potent oral efficacy, genetics-validated mechanism, and clean safety profile from late-stage trials.